But unlike classical CRC, POLE‐mutated tumors were strongly associated with unusual mutations, which exhibit rare prevalence in these genes: 65% harbored noncodon 12 KRAS mutations (G13D; V14I; D57N; E98*; K117N; A146T; K147T/E or K170Q); 20% harbored noncodon 12 NRAS mutation (Q61R; E132K; R167*); 40% harbored a non‐V600E BRAF mutation (F294L; Y633C; L312P; S602Y; Q356K; R354*; S102Y; L567V; R389C; F247L); 55% harbored a PIK3CA mutation. This evidence concerns the gene BRAF and colorectal carcinoma.